{"id":64563,"date":"2026-05-06T21:05:08","date_gmt":"2026-05-06T13:05:08","guid":{"rendered":"https:\/\/flcube.com\/?p=64563"},"modified":"2026-05-06T21:05:10","modified_gmt":"2026-05-06T13:05:10","slug":"leads-biolabs-partner-dianthus-selects-sjogrens-lupus-and-dermatomyositis-as-priority-indications-for-bifunctional-autoimmune-drug-lbl-047-following-1b-licensing-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64563","title":{"rendered":"Leads Biolabs&#8217; Partner Dianthus Selects Sj\u00f6gren&#8217;s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal"},"content":{"rendered":"\n<p><strong>Nanjing Leads Biolabs Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/9887:HKG\">HKG: 9887<\/a>)<\/strong> announced that its US partner <strong>Dianthus Therapeutics (<a href=\"https:\/\/www.google.com\/finance\/quote\/DNTH:NASDAQ\">NASDAQ: DNTH<\/a>)<\/strong> has selected <strong>Sj\u00f6gren&#8217;s disease (SjD)<\/strong>, <strong>systemic lupus erythematosus (SLE)<\/strong>, and <strong>dermatomyositis (DM)<\/strong> as the first three priority indications for clinical development of <strong>LBL-047 (DNTH212)<\/strong>, a novel bifunctional fusion protein for autoimmune diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-strategic-framework\">Partnership Structure &amp; Strategic Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Partnership Agreement<\/strong><\/td><td>October 2025<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td>Up to <strong>$1 billion<\/strong><\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Exclusive global rights outside Greater China for Dianthus<\/td><\/tr><tr><td><strong>Development Approach<\/strong><\/td><td>Joint global development collaboration<\/td><\/tr><tr><td><strong>Lead Indications<\/strong><\/td><td>Sj\u00f6gren&#8217;s disease, systemic lupus erythematosus, dermatomyositis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The strategic partnership leverages Dianthus&#8217;s expertise in autoimmune disease development while maintaining Leads Biolabs&#8217; full rights in the Greater China region.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-dual-mechanism-of-action\">Drug Profile &amp; Dual Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> LBL-047 (DNTH212) \u2013 bifunctional fusion protein<\/li>\n\n\n\n<li><strong>Structure:<\/strong> Humanized anti-BDCA2 antibody + engineered TACI extracellular domain<\/li>\n\n\n\n<li><strong>Primary Target:<\/strong> Blood dendritic cell antigen 2 (BDCA2)<\/li>\n\n\n\n<li><strong>Secondary Target:<\/strong> BAFF\/APRIL signaling pathways via TACI domain<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dual-therapeutic-actions\">Dual Therapeutic Actions:<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>pDC Depletion:<\/strong> Selectively depletes plasmacytoid dendritic cells (pDCs) to reduce type I interferon production<\/li>\n\n\n\n<li><strong>B-cell Inhibition:<\/strong> Blocks BAFF and APRIL signaling pathways to inhibit B-cell activation, differentiation, and antibody generation<\/li>\n<\/ol>\n\n\n\n<p>This dual mechanism addresses both innate and adaptive immune dysregulation characteristic of complex autoimmune diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-priority-indication-rationale\">Priority Indication Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Disease Characteristics<\/th><th>Unmet Need<\/th><\/tr><\/thead><tbody><tr><td><strong>Sj\u00f6gren&#8217;s Disease (SjD)<\/strong><\/td><td>Chronic autoimmune disorder affecting exocrine glands<\/td><td>No approved disease-modifying therapies; symptomatic treatment only<\/td><\/tr><tr><td><strong>Systemic Lupus Erythematosus (SLE)<\/strong><\/td><td>Multisystem autoimmune disease with high morbidity<\/td><td>Limited treatment options; significant residual disease activity<\/td><\/tr><tr><td><strong>Dermatomyositis (DM)<\/strong><\/td><td>Inflammatory myopathy with skin manifestations<\/td><td>Few targeted therapies; reliance on immunosuppressants<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>All three indications share common pathogenic features including type I interferon signature and B-cell hyperactivity, making them ideal targets for LBL-047&#8217;s dual mechanism of action.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Disease Market:<\/strong> Combined market for SjD, SLE, and DM exceeds $10 billion globally with significant growth potential<\/li>\n\n\n\n<li><strong>Type I Interferon Focus:<\/strong> Growing recognition of interferon pathway as central driver in multiple autoimmune conditions<\/li>\n\n\n\n<li><strong>BAFF\/APRIL Inhibition:<\/strong> Validated target class with existing therapies, but LBL-047 offers enhanced dual targeting<\/li>\n\n\n\n<li><strong>First-in-Class Potential:<\/strong> Unique bifunctional approach differentiates from single-mechanism competitors<\/li>\n\n\n\n<li><strong>Global Development Strategy:<\/strong> Joint development accelerates regulatory pathways across major markets<\/li>\n<\/ul>\n\n\n\n<p>The selection of these three high-need autoimmune indications positions LBL-047 to address significant unmet medical needs while leveraging the validated biology of both BDCA2 and TACI pathways.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and partnership milestones. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050600084_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026050600084_c.\"><\/object><a id=\"wp-block-file--media-b8013238-fd19-43f2-b215-67692529e10e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050600084_c.pdf\">2026050600084_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050600084_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b8013238-fd19-43f2-b215-67692529e10e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that its US partner Dianthus Therapeutics (NASDAQ:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4395,4242,1974,4396],"class_list":["post-64563","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-dianthus-therapeutics","tag-hkg-9887","tag-leads-biolabs","tag-nasdaq-dnth"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leads Biolabs&#039; Partner Dianthus Selects Sj\u00f6gren&#039;s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that its US partner Dianthus Therapeutics (NASDAQ: DNTH) has selected Sj\u00f6gren&#039;s disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (DNTH212), a novel bifunctional fusion protein for autoimmune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64563\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leads Biolabs&#039; Partner Dianthus Selects Sj\u00f6gren&#039;s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal\" \/>\n<meta property=\"og:description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that its US partner Dianthus Therapeutics (NASDAQ: DNTH) has selected Sj\u00f6gren&#039;s disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (DNTH212), a novel bifunctional fusion protein for autoimmune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64563\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T13:05:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-06T13:05:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64563#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64563\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leads Biolabs&#8217; Partner Dianthus Selects Sj\u00f6gren&#8217;s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal\",\"datePublished\":\"2026-05-06T13:05:08+00:00\",\"dateModified\":\"2026-05-06T13:05:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64563\"},\"wordCount\":438,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Dianthus\u202fTherapeutics\",\"HKG: 9887\",\"Leads Biolabs\",\"NASDAQ: DNTH\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64563#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64563\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64563\",\"name\":\"Leads Biolabs' Partner Dianthus Selects Sj\u00f6gren's, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-06T13:05:08+00:00\",\"dateModified\":\"2026-05-06T13:05:10+00:00\",\"description\":\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that its US partner Dianthus Therapeutics (NASDAQ: DNTH) has selected Sj\u00f6gren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (DNTH212), a novel bifunctional fusion protein for autoimmune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64563#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64563\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64563#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leads Biolabs&#8217; Partner Dianthus Selects Sj\u00f6gren&#8217;s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leads Biolabs' Partner Dianthus Selects Sj\u00f6gren's, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that its US partner Dianthus Therapeutics (NASDAQ: DNTH) has selected Sj\u00f6gren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (DNTH212), a novel bifunctional fusion protein for autoimmune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64563","og_locale":"en_US","og_type":"article","og_title":"Leads Biolabs' Partner Dianthus Selects Sj\u00f6gren's, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal","og_description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that its US partner Dianthus Therapeutics (NASDAQ: DNTH) has selected Sj\u00f6gren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (DNTH212), a novel bifunctional fusion protein for autoimmune diseases.","og_url":"https:\/\/flcube.com\/?p=64563","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-06T13:05:08+00:00","article_modified_time":"2026-05-06T13:05:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64563#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64563"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leads Biolabs&#8217; Partner Dianthus Selects Sj\u00f6gren&#8217;s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal","datePublished":"2026-05-06T13:05:08+00:00","dateModified":"2026-05-06T13:05:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64563"},"wordCount":438,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Dianthus\u202fTherapeutics","HKG: 9887","Leads Biolabs","NASDAQ: DNTH"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64563#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64563","url":"https:\/\/flcube.com\/?p=64563","name":"Leads Biolabs' Partner Dianthus Selects Sj\u00f6gren's, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-06T13:05:08+00:00","dateModified":"2026-05-06T13:05:10+00:00","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that its US partner Dianthus Therapeutics (NASDAQ: DNTH) has selected Sj\u00f6gren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (DNTH212), a novel bifunctional fusion protein for autoimmune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64563#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64563"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64563#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leads Biolabs&#8217; Partner Dianthus Selects Sj\u00f6gren&#8217;s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64563"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64563\/revisions"}],"predecessor-version":[{"id":64566,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64563\/revisions\/64566"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}